Targeting NKG2D/NKG2D ligand axis for cancer immunotherapy

Jennifer Wu*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

NKG2D is a major activation receptor on natural killer (NK) cells and a unique receptor on Cd8 T cells and subsets of NKT and γδ T cells. NKG2D is generally absent on CD4 T cells. The ligand of NKG2D (NKG2D-L) is generally absent on normal tissues, but prevalently induced on tumors cells as a response to genomic insults. Due to the unique nature of the NKG2D/NKG2D-L axis, attentions and efforts are emerging to harness the power of NKG2D/NKG2D-L for cancer immunotherapy. To support this development, this chapter will cover the basic biology of the NKG2D/NKG2D-L system and strategies to target this axis for cancer immunotherapy.

Original languageEnglish (US)
Title of host publicationNK Cells in Cancer Immunotherapy
Subtitle of host publicationSuccesses and Challenges
PublisherElsevier
Pages83-95
Number of pages13
ISBN (Electronic)9780128226209
ISBN (Print)9780128226261
DOIs
StatePublished - Jan 1 2022

Keywords

  • ATM
  • Cancer
  • Immunoreceptor
  • MICB
  • NKG2D
  • Signaling

ASJC Scopus subject areas

  • General Agricultural and Biological Sciences
  • General Biochemistry, Genetics and Molecular Biology

Fingerprint

Dive into the research topics of 'Targeting NKG2D/NKG2D ligand axis for cancer immunotherapy'. Together they form a unique fingerprint.

Cite this